This is the authors' abstract. We don't add key points for this paper.
Purpose: To characterize changes in fibrovascular membrane traction following antivascular endothelial growth factor (anti-VEGF) treatment in eyes with proliferative diabetic retinopathy. Methods: Fibrovascular membrane traction was decomposed into anteroposterior, tangential, and bridging vectors and quantitatively assessed using standardized ultrawide-field fundus imaging with navigated swept-source optical coherence tomography (OCT). Results: Five eyes of 5 patients with high-risk proliferative diabetic retinopathy demonstrated progression of fibrovascular membrane traction following intravitreal anti-VEGF injection. Ultrawide-field fundus imaging with navigated swept-source OCT showed increases in anteroposterior traction ranging from 5.3% to 62% and in tangential traction ranging from 3% to 14% compared with pre-injection measurements (follow-up interval, 1–10 weeks). Over a 6-month follow-up period, fibrovascular membrane traction remained stable in 4 eyes, whereas 1 eye developed macula-threatening traction and vision loss requiring vitrectomy. Conclusions: This retrospective series demonstrates dynamic changes in fibrovascular membrane traction following anti-VEGF therapy in proliferative diabetic retinopathy. Quantitative assessment using integrated ultra-widefield imaging and navigated swept-source OCT may provide a useful approach for monitoring tractional changes and informing clinical decision-making regarding fibrovascular membrane management. Larger prospective studies are warranted to validate these findings.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: